Details of the Drug Combination

General Information of Drug Combination (ID: DCDX22C)

• Drug Combination Name: SY-1425 + Taxol
• Indication: Mixed endometrioid and clear cell carcinoma; Status: Investigative [1]
• Component Drugs:
  SY-1425 (DMH8UF0): N.A.
  Taxol (DMUOT9V): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: IGROV1
  Zero Interaction Potency (ZIP) Score: 5.79
  Bliss Independence Score: 10.79
  Loewe Additivity Score: 3.61
  LHighest Single Agent (HSA) Score: 9.65

Molecular Interaction Atlas of This Drug Combination

Indication(s) of SY-1425

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 1	[2]
Myelodysplastic syndrome	2A37	Phase 1	[2]

SY-1425 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Retinoic acid receptor alpha (RARA)	TTW38KT	RARA_HUMAN	Agonist	[2]

Indication(s) of Taxol

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[3]
Solid tumour/cancer	2A00-2F9Z	Approved	[4]
Pancreatic cancer	2C10	Phase 3	[2]
Gastric adenocarcinoma	2B72	Phase 2	[5]
Ovarian cancer	2C73	Phase 2	[5]

Taxol Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Apoptosis regulator Bcl-2 (BCL-2)	TTJGNVC	BCL2_HUMAN	Modulator	[3]
Tubulin beta (TUBB)	TTYFKSZ	NOUNIPROTAC	Modulator	[3]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adult acute myeloid leukemia	DCUHV1X	HL-60(TB)	Investigative	[6]
Chronic myelogenous leukemia	DC46IBE	K-562	Investigative	[6]
Clear cell renal cell carcinoma	DCEUG0B	A498	Investigative	[6]
Clear cell renal cell carcinoma	DCTY9JT	786-0	Investigative	[6]
Clear cell renal cell carcinoma	DCK4XFJ	CAKI-1	Investigative	[6]
Glioblastoma	DCDPXWY	SNB-75	Investigative	[6]
Glioma	DCIJ8WD	SF-295	Investigative	[6]
Glioma	DC9FD1U	SF-268	Investigative	[6]
Papillary renal cell carcinoma	DCGF0X1	ACHN	Investigative	[6]
Plasma cell myeloma	DCJMAX6	RPMI-8226	Investigative	[6]
Renal cell carcinoma	DCB5EZV	UO-31	Investigative	[6]
Breast adenocarcinoma	DC4WN0A	MDA-MB-468	Investigative	[7]
Carcinoma	DC60YAW	MCF7	Investigative	[7]
Colon carcinoma	DCSZ8BO	KM12	Investigative	[7]
Invasive ductal carcinoma	DCQP3LK	BT-549	Investigative	[7]
Invasive ductal carcinoma	DCAMS9D	HS 578T	Investigative	[7]
Invasive ductal carcinoma	DCK989Q	T-47D	Investigative	[7]
Adenocarcinoma	DCAA956	A549	Investigative	[1]
Adenocarcinoma	DCCN6KQ	HCC-2998	Investigative	[1]
High grade ovarian serous adenocarcinoma	DCA89CV	OVCAR-8	Investigative	[1]
Large cell lung carcinoma	DCG9FXT	NCI-H460	Investigative	[1]
Lung adenocarcinoma	DCS6OK2	MDA-MB-231	Investigative	[1]
Melanoma	DCX9A17	MALME-3M	Investigative	[1]
Prostate carcinoma	DCKS9T0	PC-3	Investigative	[1]

References

• [1] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [7] Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.